Landos Biopharma (NASDAQ:LABP) stock is on the rise Monday after the company announced an acquisition deal with AbbVie (NYSE:ABBV).
AbbVie is acquiring Landos Biopharma for $20.42 per share in cash. That represents a roughly 160.8% premium over the stock’s closing price on Friday. It also comes to $137.5 million for the clinical-stage biopharmaceutical company.
In addition to this, the deal includes one non-tradable contingent value right per share. This can have a value of up to $11.14 per share, or $75 million. This is tied to the achievement of a clinical development milestone.
Roopal Thakkar, senior vice president and Chief Medical Officer of global therapeutics at AbbVie, said the following about the acquisition.
“With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn’s disease.”
How This Affects LABP Stock
Investors are excited about the deal with AbbVie, which is set to close in Q2 2024. This also brings with it heavy trading of the company’s shares. As a result, more than 365,000 units have traded on Monday afternoon. That’s well above its daily average trading volume of about 10,000 shares.
LABP stock is up 168.4% as of this writing.
Investors can find more of the most recent stock market stories ready to go at the links below!
We have all of the hottest stock market news on Monday! That includes everything happening with shares of Ocugen (NASDAQ:OCGN) stock, D-MARKET Electronic (NASDAQ:HEPS) and Tesla (NASDAQ:TSLA) stock today. You can find out more on these matters at the links below!
More Monday Stock Market News
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
